z-logo
Premium
Epidemiologic Survey of Children with End‐Stage Renal Disease
Author(s) -
Hisano Satoshi,
Tsuru Noboru,
Itoh Yuhei,
Hattori Shinzaburo,
Uchiyama Makoto,
Tamanaha Koichiroh,
Ninomiya Makoto,
Furuse Akio,
Yamagishi Minoru,
Hohjoh Minoru,
Nagano Kiyoaki,
Hashiguchi Kanehide,
Yanase Tetsuro,
Ohbu Keizo,
Mukuno Kumiko,
Kuriya Norikazu,
Yamashita Fumio
Publication year - 1990
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.1990.tb00841.x
Subject(s) - medicine , end stage renal disease , nephrotic syndrome , transplantation , peritoneal dialysis , pediatrics , continuous ambulatory peritoneal dialysis , proteinuria , dialysis , hemodialysis , urinary system , gastroenterology , urology , kidney
We performed an epidemiologic study on the basis of a questionnaire survey of 162 children with end‐stage renal disease (ESRD). Sixty‐nine (43%) of our 162 children, including 25 detected at mass screening of urine, were found by chance hematuria and/or proteinuria. The three major causes of ESRD in our children were chronic glomerulonephritis (CGN) in 56, congenital anomalies of the urinary tract in 30, and nephrotic syndrome (NS) in 27. The renal pathology in 39 children with CGN or NS was focal glomerular sclerosis in 15, diffuse mesangial GN in 7, IgA GN in 5, membranoproliferative GN in 3, membranous GN in 3, and unclassified in 6. Forms of dialysis initiated were hemodialysis in 91 children, continuous ambulatory peritoneal dialysis (PD) in 66, and intermittent PD in 5. Renal transplantation was performed on 38 children, and the graft and the patient survival rates were 76% and 89%, respectively. The survival rate of our 162 children for a mean follow‐up of 8.1 years was 77%. In conclusion, an integrated program of maintenance dialysis and transplantation provides a favorable life for children with ESRD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here